In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The US: To Go, or Not to Go?

Executive Summary

Whether or not European biotechs should establish operations in the US may seem like a no brainer: it's the biggest drugs market, with more potential partners, better funding, more promising exits for investors and a more experienced management pool than Europe. But getting there-and getting noticed-isn't easy. And since most executives agree that going to the US half-heartedly isn't worthwhile, Europe's biotechs need to think hard about when and whether they're ready to go. For a minority, setting up in the US may not be the right solution-for now.

You may also be interested in...



European Biotech Is Specialty Pharma

Europe's investment environment has forced much of the biotech sector to morph into specialty pharma. The situation isn't likely to change fast. Executives had best adapt, rather than complain.

Is Switzerland Becoming Europe's Biotech Capital?

Biogen Idec's decision to move its international headquarters from Paris to Switzerland reflects the growing size, and changing structure, of its international business. It also increases Switzerland's already strong allure as Europe's friendliest biotech hub.

GPC Looks to Nasdaq for the Best of Both Worlds

A late-June listing may help Germany's GPC Biotech AG attract investor interest and it certainly reinforces the firm's increasing Americanization. Yet the performance of lead candidate satraplatin remains the strongest determinant of GPC's valuation and near-term success.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID017698

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel